Bone disease as the first manifestation of systemic AL-amyloidosis

Cover Page

Cite item

Full Text

Abstract

Our case demonstrates severe bone disease in primary AL-amyloidosis without concomitant multiple myeloma. A 30-year-old man had spontaneous vertebral fracture Th8. A computed tomography scan suggested multiple foci of lesions in all the bones. In bone marrow and resected rib weren’t detected any tumor cells. After 15 years from the beginning of the disease, nephrotic syndrome developed. Based on the kidney biopsy, AL-amyloidosis was confirmed. Amyloid was also detected in the bowel and bone marrow. On the indirect signs (thickening of the interventricular septum 16 mm and increased NT-proBNP – 2200 pg/ml), a cardial involvement was confirmed. In the bone marrow (from three sites) was found 2.8–5% clonal plasma cells with immunophenotype СD138+, СD38dim, СD19-, СD117+, СD81-, СD27-, СD56-. FISH method revealed polysomy 5,9,15 in 3% of the nuclei. Serum free light chain Kappa 575 mg/l (ê/ë 44.9) was detected. Multiple foci of destruction with increased metabolic activity (SUVmax 3.6) were visualized on PET-CT, and an surgical intervention biopsy was performed from two foci. The number of plasma cells from the destruction foci was 2.5%, and massive amyloid deposition was detected. On CT scan foci of lesions differed from bone lesions at multiple myeloma. Bone fragments of point and linear type (button sequestration) were visualized in most of the destruction foci. The content of the lesion was low density. There was no extraossal spread from large zones of destruction. There was also spontaneous «scarring» of the some lesions (without therapy). Thus, the diagnosis of multiple myeloma was excluded on the basis based on x-ray signs, of the duration of osteodestructive syndrome (15 years), the absence of plasma infiltration in the bone marrow, including from foci of bone destruction by open biopsy. This observation proves the possibility of damage to the skeleton due to amyloid deposition and justifies the need to include AL-amyloidosis in the spectrum of differential diagnosis of diseases that occur with osteodestructive syndrome.

About the authors

L. P. Mendeleeva

National Research Center for Hematology

Author for correspondence.
Email: viktoria2102@icloud.com
ORCID iD: 0000-0002-4966-8146

д.м.н., проф., зам. ген. дир. по научной работе и инновациям ФГБУ «НМИЦ гематологии»

Russian Federation, Moscow

I. G. Rekhtina

National Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0001-5440-4340

д.м.н, зав. отд-нием химиотерапии плазмоклеточных дискразий ФГБУ «НМИЦ гематологии»

Russian Federation, Moscow

A. M. Kovrigina

National Research Center for Hematology; Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies

Email: viktoria2102@icloud.com
ORCID iD: 0000-0002-1082-8659

д.б.н., зав. патологоанатомическим отд-нием ФГБУ «НМИЦ гематологии», проф. каф. клинической лабораторной диагностики и патологической анатомии Академии ПО ФГБУ ФНКЦ

Russian Federation, Moscow

I. E. Kostina

National Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0003-4683-4118

к.м.н., зав. отд-нием рентгенологии и компьютерной томографии ФГБУ «НМИЦ гематологии»

Russian Federation, Moscow

V. A. Khyshova

National Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0002-1008-5007

клинический ординатор отд-ния химиотерапии плазмоклеточных дискразий ФГБУ «НМИЦ гематологии»

Russian Federation, Moscow

N. K. Arytyunyan

National Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0001-5952-0244

врач-гематолог, отд-ние высокодозной химиотерапии парапротеинемических гемобластозов ФГБУ «НМИЦ гематологии»

Russian Federation, Moscow

W. E. Mamonov

National Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0001-7795-4564

к.м.н., зав. ортопедическим отд-нием ФГБУ «НМИЦ гематологии»

Russian Federation, Moscow

V. G. Savthenko

National Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0001-8188-5557

акад. РАН, д.м.н., проф., ген. дир. ФГБУ «НМИЦ гематологии», гл. внештат. специалист-гематолог Минздрава России

Russian Federation, Moscow

References

  1. Swerdlow SH, Campo E, Haerris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, 2017.
  2. Kourelis TV, Kumar SK, Gertz MA, et al. J Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. Clin Oncol. 2013;31(34):4319-24. doi: 10.1200/JCO.2013.50.8499
  3. Prokaeva T, Spencer B, Kaut M, et al. Soft Tissue, Joint, and Bone Manifestations of AL Amyloidosis. Arthritis Rheum. 2007;56(11):3858-68. doi: 10.1002/art.22959
  4. Rajkumar SV, Gertz MA, Kyle RA.Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer. 1998;82:1501-5. PMID: 9554527.
  5. Review International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48. doi: 10.1016/S1470-2045(14)70442-5
  6. Wu X, Feng J, Cao X, et al. Atypical immunoglobulin light chain amyloidosis: Spontaneous vertebral compression fracture, liver involvement, and bone marrow involvement report of 3 cases and review of the literature. Medicine (Baltimore). 2016;95(36):e4603. doi: 10.1097/MD.0000000000004603
  7. Bataille R, Chappard D, Alexandre C, et al. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer. 1986;53(6):805-10. doi: 10.1038/bjc.1986.136
  8. Marcelli C, Chappard D, Rossi JF, et al. Histologic evidence of an abnormal bone remodeling in B-cell malignancies other than multiple myeloma. Cancer. 1988;62:1163-70. doi: 10.1002/1097-0142(19880915)62: 6<1163::aid-cncr2820620620>3.0.co;2-6
  9. Rossi JF, Chappard D, Marcelli C, et al. Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma. Br J Haematol. 1990;76:469-75. doi: 10.1111/j.1365-2141.1990.tb07902.x
  10. Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood. 1996;87:4762-9.
  11. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160(4):1293-9. doi: 10.1016/S0002-9440(10)62556-4

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies